# UAE Drug Database Research

## Current Situation
DailyMed integration provides ~14% success rate for UAE drug matching. This is expected because:
- DailyMed is US-specific (FDA/NLM)
- UAE has different regulatory framework
- Drug codes and formulations differ between markets
- Language and terminology variations

## UAE-Specific Drug Data Sources

### 1. UAE Ministry of Health and Prevention (MOHAP)
- **Authority**: UAE federal health authority
- **Data**: Drug registration database
- **Coverage**: All approved pharmaceutical products in UAE
- **Access**: May require official request/API access
- **Website**: https://www.mohap.gov.ae/

### 2. Dubai Health Authority (DHA)
- **Authority**: Dubai emirate health authority
- **Data**: Drug formulary and registration
- **Coverage**: Dubai-specific approvals
- **Access**: DHA drug directory (potentially accessible)
- **Website**: https://www.dha.gov.ae/

### 3. Health Authority - Abu Dhabi (HAAD)
- **Authority**: Abu Dhabi emirate health authority
- **Data**: Drug approval database
- **Coverage**: Abu Dhabi-specific approvals
- **Access**: HAAD formulary (potentially accessible)
- **Website**: https://www.haad.ae/

### 4. Saudi Food & Drug Authority (SFDA)
- **Authority**: Saudi regulatory body (GCC-wide influence)
- **Data**: Drug registration database
- **Coverage**: GCC-approved drugs (includes UAE)
- **Access**: SFDA drug database (potentially accessible)
- **Website**: https://www.sfda.gov.sa/

### 5. GCC Central Drug Registration (CDR)
- **Authority**: Gulf Cooperation Council centralized system
- **Data**: Joint drug registrations across GCC countries
- **Coverage**: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE
- **Access**: May require official request
- **Website**: https://www.gcc-sg.org/

### 6. International Options

#### European Medicines Agency (EMA)
- **Authority**: European Union regulatory body
- **Data**: EMA drug database (EudraPharm)
- **Coverage**: EU-approved drugs
- **Access**: Public API available
- **Website**: https://www.ema.europa.eu/

#### WHO ATC Classification System
- **Authority**: World Health Organization
- **Data**: Anatomical Therapeutic Chemical classification
- **Coverage**: International standard
- **Access**: Public database
- **Website**: https://www.whocc.no/

#### DrugBank
- **Authority**: University of Alberta
- **Data**: Comprehensive drug database
- **Coverage**: International drugs with detailed data
- **Access**: Commercial license required
- **Website**: https://go.drugbank.com/

## Recommended Approach

### Phase 1: Enhance Current Matching (Short-term)
1. Analyze failed matches from current DailyMed import
2. Refine matching algorithm based on failure patterns
3. Add more sophisticated fuzzy matching
4. Implement multi-stage matching strategy

### Phase 2: Regional Data Integration (Medium-term)
1. **Priority**: SFDA database (GCC-wide, likely accessible)
2. **Priority**: EMA database (European, public API available)
3. **Research**: MOHAP/DHA/HAAD accessibility
4. **Consider**: WHO ATC for international standardization

### Phase 3: Hybrid Approach (Long-term)
1. Combine multiple data sources with confidence scoring
2. Implement source hierarchy (UAE > GCC > International)
3. Create fallback chain for maximum coverage
4. Regular data synchronization

## Implementation Strategy

### Immediate Actions
1. Complete current DailyMed import for baseline data
2. Analyze failure patterns
3. Implement algorithm refinements
4. Test with sample UAE drugs

### Next Steps (1-2 weeks)
1. Research SFDA database access requirements
2. Explore EMA API integration
3. Contact MOHAP for potential data access
4. Evaluate WHO ATC integration

### Future Considerations
1. Build UAE-specific drug knowledge base
2. Implement machine learning for matching
3. Create local validation and review process
4. Establish regular data update schedule

## Success Metrics
- **Current**: 14% success rate (DailyMed only)
- **Target Phase 1**: 25-30% success rate (enhanced algorithm)
- **Target Phase 2**: 50-60% success rate (regional data)
- **Target Phase 3**: 70-80% success rate (hybrid approach)

## Notes
- UAE drug market has significant regional specificity
- Many drugs are manufactured locally or regionally
- Brand names and formulations differ from US/Europe
- Regulatory requirements and approval processes vary
- Language differences (Arabic/English) affect naming conventions